We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01477918
Recruitment Status : Unknown
Verified November 2011 by Yeon-Ho Joo, Asan Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : November 23, 2011
Last Update Posted : November 23, 2011
Information provided by (Responsible Party):
Yeon-Ho Joo, Asan Medical Center

Brief Summary:

The aim of this study is to examine the prevalence of the Metabolic syndrome(MetS) in Korean patients with schizophrenia.

Primary objective:

• To investigate the prevalence of the MetS in Korean patients with schizophrenia

Secondary objectives:

• To compare the prevalence of the MetS among 3 groups according to antipsychotics: typical antipsychotic monotherapy group, atypical antipsychotic monotherapy group, 2 or more antipsychotics group (polypharmacy)

Condition or disease
Schizophrenia Metabolic Syndrome

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Study Start Date : December 2011

Primary Outcome Measures :
  1. prevalence of metabolic syndrome (MetS)

    MetS will be diagnosed according to NCEP ATP III with the Asian-Pacific abdominal obesity criterion (≥90 cm in men, ≥85 cm in women)

    3 or more of the following criteria

    1. fasting plasma glucose >= 100 mg/dl or drug use to treat elevated glucose
    2. serum triglyceride (TG) >= 150 mg/dl or drug use to treat elevated TG
    3. HDL cholesterol level < 40mg /dl in males, < 50 mg/dl in female or drug use to treat low HDL
    4. Systolic BP >=130 mmHg, diastolic BP >=85 or drug use to treat hypertension
    5. Abdominal obesity : above described

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study will include all patients that met the following criteria:

  1. Diagnosis of schizophrenia according to DSM-IV-TR
  2. Age between 18-65 years

To obtain the representative results for the prevalence of the MetS in schizophrenic patients stratified age and gender, we plan to evaluate about one thousand patients in twenty nationwide centers.

  1. 20 centers were selected to provide the representative results of prevalence of the MetS
  2. 50 patients in each center were consecutively enrolled

Inclusion Criteria:

  • Diagnosis of schizophrenia according to DSM-IV-TR
  • Age between 18-65 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477918

Contact: Yeon-Ho Joo, Ph.D. 82-2-3010-3412 jooyh@amc.seoul.kr

Korea, Republic of
Asan medical center Not yet recruiting
Seoul, Korea, Republic of, 138-736
Contact: Yeon-Ho Joo, Ph. D.    82-2-3010-3412    jooyh@amc.seoul.kr   
Sponsors and Collaborators
Asan Medical Center

Responsible Party: Yeon-Ho Joo, Professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01477918     History of Changes
Other Study ID Numbers: MetS_1005
First Posted: November 23, 2011    Key Record Dates
Last Update Posted: November 23, 2011
Last Verified: November 2011

Keywords provided by Yeon-Ho Joo, Asan Medical Center:

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases